Eli Lilly Announces Data From Three Phase 3 Studies Of Foundayo In ACHIEVE Program Surpasses Oral Semaglutide Throughout Primary, Secondary Endpoints In Adults With Type 2 Diabetes

뉴스 본문을 불러오고 있어요.

Eli Lilly Announces Data From Three Phase 3 Studies Of Foundayo In ACHIEVE Program Surpasses Oral Semaglutide Throughout Primary, Secondary Endpoints In Adults With Type 2 Diabetes | 웨이프 WAPE

Eli Lilly Announces Data From Three Phase 3 Studies Of Foundayo In ACHIEVE Program Surpasses Oral Semaglutide Throughout Primary, Secondary Endpoints In Adults With Type 2 Diabetes

기사 요약

관련 종목

댓글 —